Harnessing the power of the immune system has revolutionised treatment options for patients. However there are concerns about unwanted immune responses leading to serious adverse events.  Regulatory agencies require an assessment of a biotherapeutic’s potential to trigger these unwanted responses. This presentation will focus on solutions to address the potential for unwanted immune responses and why doing so early in candidate selection can have a very positive impact on development time.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center